115 related articles for article (PubMed ID: 15894559)
1. Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer.
Chang KT; Huang CY; Tsai CM; Chiu CH; Lok YY
Am J Physiol Lung Cell Mol Physiol; 2005 Sep; 289(3):L438-45. PubMed ID: 15894559
[TBL] [Abstract][Full Text] [Related]
2. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells.
Chang KT; Tsai CM; Chiou YC; Chiu CH; Jeng KS; Huang CY
Am J Physiol Lung Cell Mol Physiol; 2005 Sep; 289(3):L446-53. PubMed ID: 15894558
[TBL] [Abstract][Full Text] [Related]
3. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
4. [Research on the relationship between non-small cell lung cancer with neuroendocrine differentiation and the biological characteristics and prognosis].
Zhang J; Zheng K; Guo Y; Zhang P; Zhan Z
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):873-6. PubMed ID: 20840816
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay.
Hida T; Ueda R; Takahashi T; Watanabe H; Kato T; Suyama M; Sugiura T; Ariyoshi Y; Takahashi T
Cancer Res; 1989 Sep; 49(17):4785-90. PubMed ID: 2547517
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary large cell carcinoma expressing neuroendocrine markers: the morphological, biological, and neuroendocrine features of their cell lines and surgical cases.
Kasai K; Kameya T; Kawakubo Y; Sato Y; Wada C; Itoh H
Jpn J Cancer Res; 1992 Sep; 83(9):1002-10. PubMed ID: 1331003
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).
Zhu Y; Liu C; Cui Y; Nadiminty N; Lou W; Gao AC
Prostate; 2014 Aug; 74(11):1086-94. PubMed ID: 24819501
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Petrović M; Baskić D; Banković D; Ilić N
Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
[TBL] [Abstract][Full Text] [Related]
10. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
11. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Kim J; Adam RM; Solomon KR; Freeman MR
Endocrinology; 2004 Feb; 145(2):613-9. PubMed ID: 14563701
[TBL] [Abstract][Full Text] [Related]
12. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
13. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype.
Zelivianski S; Verni M; Moore C; Kondrikov D; Taylor R; Lin MF
Biochim Biophys Acta; 2001 May; 1539(1-2):28-43. PubMed ID: 11389966
[TBL] [Abstract][Full Text] [Related]
14. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .
Spiotto MT; Chung TD
Prostate; 2000 Feb; 42(3):186-95. PubMed ID: 10639189
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours.
Sundaresan V; Reeve JG; Stenning S; Stewart S; Bleehen NM
Br J Cancer; 1991 Aug; 64(2):333-8. PubMed ID: 1654075
[TBL] [Abstract][Full Text] [Related]
16. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
17. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression.
Wang HQ; Jin JJ; Wang J
J Biochem Mol Toxicol; 2014 Jan; 28(1):39-45. PubMed ID: 24395429
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal activation between IL-6/STAT3 and NOX4/Akt signalings promotes proliferation and survival of non-small cell lung cancer cells.
Li J; Lan T; Zhang C; Zeng C; Hou J; Yang Z; Zhang M; Liu J; Liu B
Oncotarget; 2015 Jan; 6(2):1031-48. PubMed ID: 25504436
[TBL] [Abstract][Full Text] [Related]
19. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
20. Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer.
Chen Y; Nowak I; Huang J; Keng PC; Sun H; Xu H; Wei G; Lee SO
J Thorac Oncol; 2014 Jan; 9(1):50-8. PubMed ID: 24346093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
